<DOC>
	<DOCNO>NCT00727038</DOCNO>
	<brief_summary>Neovascular glaucoma potentially debilitate disease eye . Vascular eye disease diabetes vein occlusion cause retina release factor promote growth abnormal blood vessel . These abnormal vessel grow drainage mechanism eye cause pressure eye markedly increase . This potentially cause irreversible damage optic nerve glaucoma lead permanent blindness painful eye . Conventional treatment include laser freezing therapy take week cause regression abnormal blood vessel growth . This delay often result permanent vision loss pain . New medication target immediately reduce blood vessel growth may aid treatment disease .</brief_summary>
	<brief_title>Lucentis New Onset Neovascular Glaucoma</brief_title>
	<detailed_description>Hypothesis : Intravitreal injection Lucentis prior conventional treatment neovascular glaucoma improve overall outcome compare conventional treatment alone . Specific Aims : To determine pre-treatment single intravitreal injection Lucentis prior conventional treatment prevents severe vision loss improve intraocular pressure control compare conventional treatment alone . Neovascular glaucoma potentially devastate consequence fibrovascular proliferation anterior chamber angle subsequent obstruction trabecular meshwork . The production peripheral anterior synechiae along trabecular meshwork lead progressive angle closure . The subsequent elevation intraocular pressure difficult manage , often lead rapid progression glaucoma significant loss vision . Enucleation blind , painful eye secondary neovascular glaucoma uncommon sequela . Neovascular glaucoma many etiologic cause , vast majority result retinal ischemia secondary relatively common disease central retinal vein occlusion , proliferative diabetic retinopathy ocular ischemic syndrome ( carotid stenosis ) . ( Sivac-Callcott et al. , 2001 ) Vascular endothelial growth factor likely major contributor development angle iris neovascularization . ( Ferrara , 2004 ) Although panretinal photocoagulation and/or cryoablation mainstays conventional treatment neovascular glaucoma , delay therapeutic effect intervention often result formation peripheral anterior synechiae permanent angle closure . Recent limit case series demonstrate role bevacizumab ( Avastin ) reduce rubeosis iridis adjunct neovascular glaucoma . ( Grisanti et al. , 2006 ; Davidorf et al. , 2006 ; Iliev et al. , 2006 ; Kahook , Schuman , Noecker , 2006 ) However , prospective study examine potential utility anti-vascular endothelial growth factor agent treatment neovascular glaucoma . Intravitreal Lucentis standard care treatment exudative macular degeneration . Pharmacologic agent Lucentis , selectively inhibit vascular endothelial growth factor may provide important therapeutic adjunct treatment neovascular glaucoma immediately cause regression angle neovascularization thereby provide window permanent treatment laser cryotherapy .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Neovascular</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age &gt; 21 year Diagnosis neovascular glaucoma ( angle neovascularization without iris neovascularization IOP &gt; 21 mm Hg &gt; 5 mm Hg IOP compare fellow eye ) . Neovascular glaucoma secondary retinal ischemia ( central retinal vein occlusion , proliferative diabetic retinopathy , ocular ischemic syndrome , etc . ) Pregnancy ( positive pregnancy test ) lactation premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD , contraceptive hormone implant patch . Prior enrollment study Any condition investigator believe would pose significant hazard subject investigational therapy initiate Participation another simultaneous medical investigation trial &gt; 270 degree close trabecular meshwork ( closure secondary peripheral anterior synechiae ) History active inflammatory , infectious , idiopathic keratitis preclude view anterior segment structure . Previous intravitreal injection ranibizumab bevacizumab either eye .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>glaucoma</keyword>
	<keyword>neovascular glaucoma</keyword>
	<keyword>new onset glaucoma</keyword>
	<keyword>retinal ischemia</keyword>
	<keyword>central retinal vein occlusion</keyword>
	<keyword>proliferative diabetic retinopathy</keyword>
	<keyword>ocular ischemic syndrome</keyword>
	<keyword>carotid stenosis</keyword>
	<keyword>vascular endothelial growth factor</keyword>
	<keyword>neovascular</keyword>
</DOC>